Biosimilar and generic drug makers have voiced favor over the speedier FDA promised by President Trump. The agency will be aiming to approve more drugs than it did in 2016, when it reached an all-time high of 600 new patents. The quicker approval times may eliminate some approval costs and increase competition between generic and brand-name pharmaceutical makers, which may see reduced prices for patients and payers. Read the full article here.